lding a $0.3bn peak sales opportunity See inside this note for our detailed review of the Bladder Cancer opportunity. • Roche continues to explore PD-L1 in further tumour types, although there are no timelines for disclosure or data presentation: On the IQ'I4 conference call Roche highlighted that t